keyword
https://read.qxmd.com/read/38616361/characteristics-and-treatment-of-acute-myeloid-neoplasms-with-cutaneous-involvement-in-infants-up-to-6%C3%A2-months-of-age-a-retrospective-study
#21
JOURNAL ARTICLE
Juliette Renaud, Bianca F Goemans, Franco Locatelli, Martina Pigazzi, Shelagh Redmond, Claudia E Kuehni, Alice Destaillats, Todd A Alonzo, Robert B Gerbing, Alan Gamis, Richard Aplenc, Raffaele Renella, Todd Cooper, Francesco Ceppi
BACKGROUND: Myeloid neoplasms account for 50% of cases of pediatric leukemias in infants. Approximately 25%-50% of patients with newborn leukemia have cutaneous extramedullary disease (EMD). In less than 10% of patients, aleukemic leukemia cutis or isolated extramedullary disease with cutaneous involvement (cEMD) occurs when skin lesions appear prior to bone marrow involvement and systemic symptoms. Interestingly, in acute myeloid leukemia with cutaneous EMD (AML-cEMD) and cEMD, spontaneous remissions have been reported...
April 14, 2024: Pediatric Blood & Cancer
https://read.qxmd.com/read/38615229/hemangioblastoma-an-uncommon-cause-of-polycythemia-in-a-child
#22
JOURNAL ARTICLE
Surabhi Aryal, Arun Kumar Sharma
Polycythemia is a rare condition in children. Myeloproliferative neoplasms, including polycythemia vera although rare, is an important cause of childhood primary polycythemia. Secondary polycythemia is more common in children due to conditions causing hypoxia or due to pathologic erythropoietin production in malignancies like renal cell carcinoma, Wilms tumor or Hepatocellular carcinoma. Central nervous system hemangioblastoma is one of the rare causes of polycythemia. We report a 13-year-old girl with primarily neurological symptoms identified to be polycythemic during routine evaluation...
March 22, 2024: Journal of Nepal Health Research Council
https://read.qxmd.com/read/38615034/mechanistic-insights-and-the-clinical-prospects-of-targeted-therapies-for-glioblastoma-a-comprehensive-review
#23
REVIEW
Yating Shen, Dexter Kai Hao Thng, Andrea Li Ann Wong, Tan Boon Toh
Glioblastoma (GBM) is a fatal brain tumour that is traditionally diagnosed based on histological features. Recent molecular profiling studies have reshaped the World Health Organization approach in the classification of central nervous system tumours to include more pathogenetic hallmarks. These studies have revealed that multiple oncogenic pathways are dysregulated, which contributes to the aggressiveness and resistance of GBM. Such findings have shed light on the molecular vulnerability of GBM and have shifted the disease management paradigm from chemotherapy to targeted therapies...
April 13, 2024: Experimental Hematology & Oncology
https://read.qxmd.com/read/38614069/osimertinib-plus-local-treatment-for-brain-metastases-versus-osimertinib-alone-in-patients-with-egfr-mutant-non-small-cell-lung-cancer
#24
JOURNAL ARTICLE
Takehiro Tozuka, Rintaro Noro, Hideaki Mizutani, Futoshi Kurimoto, Taiki Hakozaki, Kakeru Hisakane, Tomoyuki Naito, Satoshi Takahashi, Namiko Taniuchi, Chika Yajima, Yukio Hosomi, Takashi Hirose, Yuji Minegishi, Tetsuya Okano, Koichiro Kamio, Tomoyoshi Yamaguchi, Masahiro Seike
OBJECTIVES: Osimertinib is a standard treatment for patients with EGFR-mutant non-small cell lung cancer (NSCLC) and is highly effective for brain metastases (BMs). However, it is unclear whether local treatment (LT) for BMs prior to osimertinib administration improves survival in EGFR-mutant NSCLC. We aimed to reveal the survival benefit of upfront local treatment (LT) for BMs in patients treated with osimertinib. MATERIALS AND METHODS: This multicenter retrospective study included consecutive patients with EGFR mutation (19del or L858R)-positive NSCLC who had BMs before osimertinib initiation between August 2018 and October 2021...
March 24, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38611105/spinal-meningiomas-a-comprehensive-review-and-update-on-advancements-in-molecular-characterization-diagnostics-surgical-approach-and-technology-and-alternative-therapies
#25
REVIEW
Danielle D Dang, Luke A Mugge, Omar K Awan, Andrew D Gong, Andrew A Fanous
Spinal meningiomas are the most common intradural, extramedullary tumor in adults, yet the least common entity when accounting for all meningiomas spanning the neuraxis. While traditionally considered a benign recapitulation of their intracranial counterpart, a paucity of knowledge exists regarding the differences between meningiomas arising from these two anatomic compartments in terms of histopathologic subtypes, molecular tumor biology, surgical principles, long-term functional outcomes, and recurrence rates...
April 7, 2024: Cancers
https://read.qxmd.com/read/38611071/dexamethasone-in-patients-with-glioblastoma-a-systematic-review-and-meta-analysis
#26
REVIEW
Pierre Scheffler, Christian Fung, Shahan Momjian, Dominik Koessinger, Levin Häni, Nicolas Neidert, Jakob Straehle, Florian Volz, Oliver Schnell, Jürgen Beck, Amir El Rahal
OBJECTIVE: Glioblastomas are the most common primary central nervous system (CNS) tumors. Although modern management strategies have modestly improved overall survival, the prognosis remains dismal, with treatment side effects often impinging on the clinical course. Glioblastomas cause neurological dysfunction by infiltrating CNS tissue and via perifocal oedema formation. The administration of steroids such as dexamethasone is thought to alleviate symptoms by reducing oedema. However, despite its widespread use, the evidence for the administration of dexamethasone is limited and conflicting...
April 1, 2024: Cancers
https://read.qxmd.com/read/38611021/differential-competitive-growth-of-transgenic-subclones-of-neuroblastoma-cells-expressing-different-levels-of-cathepsin-d-co-cultured-in-2d-and-3d-in-response-to-egf-implications-in-tumor-heterogeneity-and-metastasis
#27
JOURNAL ARTICLE
Eleonora Secomandi, Andrea Esposito, Giulia Camurani, Chiara Vidoni, Amreen Salwa, Chiara Lualdi, Letizia Vallino, Alessandra Ferraresi, Ciro Isidoro
Neuroblastoma (NB) is an embryonal tumor arising from the sympathetic central nervous system. The epidermal growth factor (EGF) plays a role in NB growth and metastatic behavior. Recently, we have demonstrated that cathepsin D (CD) contrasts EGF-induced NB cell growth in 2D by downregulating EGFR/MAPK signaling. Aggressive NB is highly metastatic to the bone and the brain. In the metastatic process, adherent cells detach to form clusters of suspended cells that adhere once they reach the metastatic site and form secondary colonies...
March 29, 2024: Cancers
https://read.qxmd.com/read/38610927/intracranial-efficacy-of-atezolizumab-bevacizumab-carboplatin-and-paclitaxel-in-real-world-patients-with-non-small-cell-lung-cancer-and-egfr-or-alk-alterations
#28
JOURNAL ARTICLE
Marcus Rathbone, Conor O'Hagan, Helen Wong, Adeel Khan, Timothy Cook, Sarah Rose, Jonathan Heseltine, Carles Escriu
Contrary to Pemetrexed-containing chemo-immunotherapy studies, Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel (ABCP) treatment has consistently shown clinical benefit in prospective studies in patients with lung cancer and actionable mutations, where intracranial metastases are common. Here, we aimed to describe the real-life population of patients fit to receive ABCP after targeted therapy and quantify its clinical effect in patients with brain metastases. Patients treated in Cheshire and Merseyside between 2019 and 2022 were identified...
March 22, 2024: Cancers
https://read.qxmd.com/read/38609519/central-neurocytoma-exhibits-radial-glial-cell-signatures-with-fgfr3-hypomethylation-and-overexpression
#29
JOURNAL ARTICLE
Yeajina Lee, Tamrin Chowdhury, Sojin Kim, Hyeon Jong Yu, Kyung-Min Kim, Ho Kang, Min-Sung Kim, Jin Wook Kim, Yong-Hwy Kim, So Young Ji, Kihwan Hwang, Jung Ho Han, Jinha Hwang, Seong-Keun Yoo, Kyu Sang Lee, Gheeyoung Choe, Jae-Kyung Won, Sung-Hye Park, Yong Kyu Lee, Joo Heon Shin, Chul-Kee Park, Chae-Yong Kim, Jong-Il Kim
We explored the genomic events underlying central neurocytoma (CN), a rare neoplasm of the central nervous system, via multiomics approaches, including whole-exome sequencing, bulk and single-nuclei RNA sequencing, and methylation sequencing. We identified FGFR3 hypomethylation leading to FGFR3 overexpression as a major event in the ontogeny of CN that affects crucial downstream events, such as aberrant PI3K-AKT activity and neuronal development pathways. Furthermore, we found similarities between CN and radial glial cells based on analyses of gene markers and CN tumor cells and postulate that CN tumorigenesis is due to dysregulation of radial glial cell differentiation into neurons...
April 12, 2024: Experimental & Molecular Medicine
https://read.qxmd.com/read/38606859/secondary-cancer-after-androgen-deprivation-therapy-in-prostate-cancer-a-nationwide-study
#30
JOURNAL ARTICLE
Jae Heon Kim, Gi Hwan Bae, Jaehun Jung, Tae Il Noh
PURPOSE: Androgen signaling is associated with various secondary cancer, which could be promising for potential treatment using androgen deprivation therapy (ADT). This study investigated whether ADT use was associated with secondary cancers other than prostate cancer in a nationwide population-based cohort. MATERIALS AND METHODS: A total, 278,434 men with newly diagnosed prostate cancer between January 1, 2002 and December 31, 2017 were identified. After applying the exclusion criteria, 170,416 men were enrolled...
March 14, 2024: World Journal of Men's Health
https://read.qxmd.com/read/38606112/incidence-of-second-primary-cancers-in-patients-with-retinoblastoma-a-systematic-review-and-meta-analysis
#31
Jinfeng Sun, Xiuli Gu, Liangjun Wang
INTRODUCTION: This systematic review and meta-analysis aimed to examine the risk of second primary cancers (SPCs) among retinoblastoma (Rb) patients, both hereditary and nonhereditary. Previous studies have reported on the long-term risk of SPCs in these patient populations, but a comprehensive synthesis of the existing evidence is lacking. METHODS: A systematic search was conducted in PubMed, EMBASE, and Cochrane Library from inception to 12 March 2023, supplemented by manual screening...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38605928/targeted-therapeutic-options-in-early-and-metastatic-nsclc-overview
#32
REVIEW
Gabriella Gálffy, Éva Morócz, Réka Korompay, Réka Hécz, Réka Bujdosó, Rita Puskás, Tímea Lovas, Eszter Gáspár, Kamel Yahya, Péter Király, Zoltán Lohinai
The complex therapeutic strategy of non-small cell lung cancer (NSCLC) has changed significantly in recent years. Disease-free survival increased significantly with immunotherapy and chemotherapy registered in perioperative treatments, as well as adjuvant registered immunotherapy and targeted therapy (osimertinib) in case of EGFR mutation. In oncogenic-addictive metastatic NSCLC, primarily in adenocarcinoma, the range of targeted therapies is expanding, with which the expected overall survival increases significantly, measured in years...
2024: Pathology Oncology Research: POR
https://read.qxmd.com/read/38605228/lymphatic-vessels-in-the-age-of-cancer-immunotherapy
#33
REVIEW
Triantafyllia Karakousi, Tenny Mudianto, Amanda W Lund
Lymphatic transport maintains homeostatic health and is necessary for immune surveillance, and yet lymphatic growth is often associated with solid tumour development and dissemination. Although tumour-associated lymphatic remodelling and growth were initially presumed to simply expand a passive route for regional metastasis, emerging research puts lymphatic vessels and their active transport at the interface of metastasis, tumour-associated inflammation and systemic immune surveillance. Here, we discuss active mechanisms through which lymphatic vessels shape their transport function to influence peripheral tissue immunity and the current understanding of how tumour-associated lymphatic vessels may both augment and disrupt antitumour immune surveillance...
April 11, 2024: Nature Reviews. Cancer
https://read.qxmd.com/read/38604814/oma1-competitively-binds-to-hspa9-to-promote-mitophagy-and-activate-the-cgas-sting-pathway-to-mediate-gbm-immune-escape
#34
JOURNAL ARTICLE
Wen de Zhu, Jin Rao, Li Hua Zhang, Ka Ming Xue, Lin Li, Jun Jun Li, Qian Zhi Chen, Rong Fu
BACKGROUND: Immunotherapy with checkpoint inhibitors, especially those targeting programmed death receptor 1 (PD-1)/PD-1 ligand (PD-L1), is increasingly recognized as a highly promising therapeutic modality for malignancies. Nevertheless, the efficiency of immune checkpoint blockade therapy in treating glioblastoma (GBM) is constrained. Hence, it is imperative to expand our comprehension of the molecular mechanisms behind GBM immune escape (IE). METHODS: Protein chip analysis was performed to screen aberrantly expressed OMA1 protein in PD-1 inhibitor sensitive or resistant GBM...
April 11, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38604733/impact-of-susan-denoising-and-combat-harmonization-on-machine-learning-model-performance-for-malignant-brain-neoplasms
#35
JOURNAL ARTICLE
Girish Bathla, Neetu Soni, Ian T Mark, Yanan Liu, Nicholas B Larson, Blake A Kassmeyer, Suyash Mohan, John C Benson, Saima Rathore, Amit Agarwal
BACKGROUND AND PURPOSE: Feature variability in radiomics studies due to technical and magnet strength parameters is well known and may be addressed through various pre-processing methods. However, very few studies have evaluated downstream impact of variable pre-processing on model classification performance in a multi-class setting. We sought to evaluate the impact of SUSAN denoising and ComBat harmonization on model classification performance. MATERIALS AND METHODS: A total of 493 cases (410 internal and 83 external dataset) of glioblastoma (GB), intracranial metastatic disease (IMD) and primary CNS lymphoma (PCNSL) underwent semi-automated 3D-segmentation post baseline image processing (BIP) consisting of resampling, realignment, co-registration, skull stripping and image normalization...
April 11, 2024: AJNR. American Journal of Neuroradiology
https://read.qxmd.com/read/38603654/cns-antitumor-activity-of-amivantamab-with-osimertinib-in-epidermal-growth-factor-receptor-mutated-non-small-cell-lung-cancer-with-acquired-mesenchymal-epithelial-transition-amplification-resistance-mechanism-a-case-report
#36
JOURNAL ARTICLE
Ebaa Al-Obeidi, Karen Kelly, David R Gandara, Jonathan W Riess
NSCLC w/EGFRex19del & MET amp: durable intracranial + systemic response to amivantamab/osimertinib.
April 2024: JCO Precision Oncology
https://read.qxmd.com/read/38603567/organ-involvement-in-adults-with-bpdcn-is-associated-with-sun-exposure-history-tet2-and-ras-mutations-and-survival
#37
JOURNAL ARTICLE
Shai Shimony, Julia H Keating, Christopher J Fay, Marlise R Luskin, Donna S Neuberg, Nicole R LeBoeuf, Andrew A Lane
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) can involve skin, bone marrow (BM), central nervous system (CNS), and non-CNS extramedullary sites. Preclinical models demonstrated clonal advantage of TET2-mutated plasmacytoid dendritic cells exposed to UV radiation. However, whether sun exposure, disease characteristics, and patient survival are clinically related is unclear. We classified 66 BPDCN patients based on organ involvement at diagnosis as skin only (n=19), systemic plus skin (n=33), or systemic only (n=14)...
April 11, 2024: Blood Advances
https://read.qxmd.com/read/38598668/liquid-biopsy-for-improving-diagnosis-and-monitoring-of-cns-lymphomas-a-rano-review
#38
JOURNAL ARTICLE
Lakshmi Nayak, Chetan Bettegowda, Florian Scherer, Norbert Galldiks, Manmeet Ahluwalia, Alexander Baraniskin, Louisa von Baumgarten, Jacoline E C Bromberg, Andrés J M Ferreri, Christian Grommes, Khê Hoang-Xuan, Julia Kühn, James L Rubenstein, Roberta Rudà, Michael Weller, Susan M Chang, Martin J van den Bent, Patrick Y Wen, Riccardo Soffietti
BACKGROUND: The utility of liquid biopsies is well documented in several extracranial and intracranial (brain/leptomeningeal metastases, gliomas) tumors. METHODS: The RANO (Response Assessment in Neuro-Oncology) group has set up a multidisciplinary Task Force to critically review the role of blood and CSF-liquid biopsy in central nervous system lymphomas, with a main focus on primary central nervous system lymphomas (PCNSL). RESULTS: Several clinical applications are suggested: diagnosis of PCNSL in critical settings (elderly or frail patients, deep locations, steroids responsiveness), definition of minimal residual disease, early indication of tumor response or relapse following treatments and prediction of outcome...
April 10, 2024: Neuro-oncology
https://read.qxmd.com/read/38598534/the-utility-of-prostate-specific-membrane-antigen-11-pet-in-detection-and-management-of-central-nervous-system-neoplasms
#39
JOURNAL ARTICLE
Mina Dawod, Evan Rush, Paul B Nagib, Jessica Aduwo, Pranav Bodempudi, Emmanuel Appiah-Kubi
We present a case series of 5 patients diagnosed with schwannoma and 1 patient diagnosed with astrocytoma who underwent PSMA PET imaging for tumor detection. We retrospectively analyzed the records of 4 male and 2 female patients (mean age, 53.2 ± 13.2) who underwent PSMA PET imaging between March and September 2023. PET interpretation showed increased Ga-PSMA-11 accumulation in all patients with a mean SUVmax of 3.11 ± 1.8. This series underscores PSMA PET's potential for CNS neoplasm detection.
April 5, 2024: Clinical Nuclear Medicine
https://read.qxmd.com/read/38597999/recent-advances-in-liquid-biopsy-of-central-nervous-system-lymphomas-case-presentations-and-review-of-the-literature
#40
JOURNAL ARTICLE
Manabu Natsumeda, Satoshi Shibuma, Haruhiko Takahashi, Jotaro On, Yoshihiro Mouri, Kaoru Tomikawa, Hidemoto Fujiwara, Jun Watanabe, Yoshihiro Tsukamoto, Masayasu Okada, Rui Takeda, Hiroshi Shimizu, Jun Takizawa, Akiyoshi Kakita, Makoto Oishi
Surgical biopsy is the gold standard for diagnosing central nervous system (CNS) lymphomas. However, reliable liquid biopsy methods for diagnosing CNS lymphomas have quickly developed and have been implicated in clinical decision-making. In the current report, we introduce two patients for whom liquid biopsy was essential for diagnosing CNS lymphomas and discuss the rapidly growing applications of this technology.
April 10, 2024: Brain Tumor Pathology
keyword
keyword
77131
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.